Product Images Donepezil Hydrochloride

The text describes a graph showing ADAS-cog Change from Baseline for a clinical trial. The graph shows the mean with standard error at various timepoints and compares the effect of two different doses of Donepezil Hydrochloride, a medication for cognitive impairment, with a placebo. The x-axis shows the weeks of drug treatment and the y-axis shows the change in ADAS-cog score from baseline. The graph indicates a clinical improvement, with a reduction in ADAS-cog score, for individuals taking Donepezil Hydrochloride compared to those taking a placebo.*

This appears to be a graph showing the cumulative percentage of patients on Donepezil Hydrochloride 10mg/day versus placebo, measured by the ADCS-ADL change from Baseline. The graph indicates that there is a significant improvement in ADL scores for those taking donepezil versus those taking a placebo.*

This is a graph that shows the clinical improvement or decline of patients who were given either 10mg/day or 23mg/day of Donepezil Hydrochloride. The graph spans over 24 weeks of drug treatment.*

The text appears to be a chart or a graph showing the cumulative percentage of patients who experienced a change in SIB (Severe Impairment Battery) score from baseline after taking two types of medications: Donepezil Hydrochloride at 23mg/day and Donepezil Hydrochloride at an unknown dose. The chart also displays the SIB change from baseline in percentages. Therefore, it seems to be a graphic representation of a study that compared the effectiveness of different dosages of Donepezil Hydrochloride on patients over time.*

The text appears to be a graph showing the percentage of patients who have had a change in their CIBIC-plus rating based on their dosage of Donepezil Hydrochloride (either 10mg/day or 23mg/day). The graph includes categories for Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse.*

This appears to be a chart showing the results of a study comparing the effects of Donepezil (hydrochloride 5mg and 10mg) and a placebo on patients with ADAS-cog. The chart displays the cumulative percentage of patients in each group and the change in ADAS-cog scores from baseline at various intervals.*

This appears to be a table showing the percentage of patients taking different dosages of Donepezil Hydrochloride and Placebo and their corresponding rating change based on the CIBIC-plus (Clinician's Interview-Based Impression of Change plus caregiver input) scale.*

This appears to be a chart or graph displaying the cumulative percentage of patients who experienced a change in ADAS-cog (Alzheimer's Disease Assessment Scale cognitive subscale) score over time while being treated with Donepezil Hydrochloride at various doses or with a placebo. The chart shows percentages for patients with a decrease in score (improvement) of 7 points, 4 points, or no change, and is organized by treatment group and change from baseline.*

Not-Available.*

This appears to be a chart or graph displaying the change in ADCS-ADL (a measure of functional ability in patients with dementia) from baseline over a period of 3-6 months of drug treatment with either donepezil hydrochloride 10mg/day or a placebo. The mean scores are shown but there is no indication of what the units are. There is also a heading mentioning "Clinical Improvement" and a baseline score, but it's unclear how these relate to the rest of the chart without additional context.*

This is a medication package containing Donepezil Hel 5™ tablet with a dosage of 10mg produced by Eryant Ranch Bunbank. It is designed to treat certain mental and nerve disorders, such as Alzheimer's disease. The package also contains instructions to be followed as prescribed by the doctor. The medication should be stored at room temperature, and the package contains 30 tablets that expire on a specific date indicated by MMYY. The NDC number is 7133504161, and the code is 052191113986.*